Pasithea Therapeutics Corp. (KTTAW) Share-based Compensation (2021 - 2026)

Pasithea Therapeutics has disclosed Share-based Compensation across 6 years of filings, most recently posting $7.6 million for Q2 2026.

• In Q2 2026, Share-based Compensation rose 4890.16% year-over-year to $7.6 million; the TTM figure through Jun 2026 stood at $7.6 million (up 4890.16% YoY), while the FY2025 annual figure was $1.7 million, up 117.9% from the prior year.
• Share-based Compensation came in at $7.6 million for Q2 2026 at Pasithea Therapeutics, up from $1.7 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $15.4 million in Q1 2023 to a low of $69940.0 in Q4 2023.
• Average Share-based Compensation over 5 years is $3.3 million, with a median of $448801.0 recorded in 2022.
• Year-over-year, Share-based Compensation surged 6566.67% in 2022 and sank 98.79% in 2024.
• Over 5 years, Share-based Compensation stood at $156174.0 in 2022, then slumped by 55.22% to $69940.0 in 2023, then surged by 69.26% to $118383.0 in 2024, then dropped by 25.43% to $88277.0 in 2025, then jumped by 8453.77% to $7.6 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $7.6 million in Q2 2026, $1.7 million in Q1 2026, and $88277.0 in Q4 2025.